Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

被引：3

作者：

Ardizzoni, Andrea

Razis, Evangelia

Lichinitser, Mikhail

Yilmaz, Ugur

Grigorescu, Alexandru C.

Morero, Jose Luis

Skrickova, Jana

Cervantes, Guadalupe

Gottfried, Maya

Van Meerbeeck, Jan

机构：

[1] Univ Parma, Parma, Italy

[2] Hygeia Hosp, Athens, Greece

[3] NN Blochin Russian Oncol Res Ctr, Moscow, Russia

[4] Dokuz Eylu Univ, Med Fac, Izmir, Turkey

[5] Bucharest Oncol Inst, Bucharest, Romania

[6] Hosp Maria Ferrer, Buenos Aires, DF, Argentina

[7] Univ Hosp Brno, Brno, Czech Republic

[8] ISSSTE, Hosp Noviembre Ctr Medico, Mexico City, DF, Mexico

[9] Meir Sapir Med Ctr, Kefar Sava, Israel

[10] Univ Hosp, Ghent, Belgium

来源：

JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期

关键词：

D O I：

10.1097/01.JTO.0000283158.26734.bc

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S342 / S342

页数：1

共 50 条

[31] Initial safety results from an expanded access program (EAP) with erlotinib in non-small-cell lung cancer (NSCLC) in germany
Reck, Martin
Eberhardt, W.
Schneider, Claus-Peter
von Pawel, J.
Spengler, W.
Guetz, Sylvia
Schuette, Wolfgang
Laack, Heinz-Eckart
Ko, Y-D.
von-Roemer, Kathrin Schott
ANNALS OF ONCOLOGY, 2006, 17 : 250 - 250
[32] EVEROLIMUS PLUS ERLOTINIB VERSUS ERLOTINIB ALONE IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Bennouna, J.
Besse, B.
Leighl, N. B.
Blais, N.
Traynor, A. M.
Papadimitrakopoulou, V.
Klimovsky, J.
Jappe, A.
Jehl, V.
Johnson, B. E.
ANNALS OF ONCOLOGY, 2010, 21 : 140 - 140
[33] Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Leigh, Natasha B.
Hellmann, Matthew D.
Hui, Rina
Carcereny, Enric
Felip, Enriqueta
Ahn, Myung-Ju
Eder, Joseph Paul
Balmanoukian, Ani S.
Aggarwal, Charu
Horn, Leora
Patnaik, Amita
Gubens, Matthew
Ramalingam, Suresh S.
Lubiniecki, Gregory M.
Zhang, Jin
Piperdi, Bilal
Garon, Edward B.
LANCET RESPIRATORY MEDICINE, 2019, 7 (04): : 347 - 357
[34] A cost utility analysis of erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC)
Bradbury, P. A.
Jang, R.
Isogai, P.
Mittmann, N.
Evans, W.
Shepherd, F. A.
Leighl, N. B.
Ng, R.
VALUE IN HEALTH, 2008, 11 (03) : A72 - A72
[35] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Merimsky, O.
Cheng, A. C.
Reck, M.
Au, S. K.
von Pawel, J.
ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
[36] Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer
Lee, Jin Hwa
Lee, Kyoung Eun
Ryu, Yon Ju
Chun, Eun Mi
Chang, Jung Hyun
TUBERCULOSIS AND RESPIRATORY DISEASES, 2009, 66 (04) : 280 - 287
[37] Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer
Passaro, Antonio
Alesini, Daniele
Pochesci, Alessia
Cortesi, Enrico
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 646 - 650
[38] A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
Kelly, R. J.
Shepherd, F. A.
Krivoshik, A.
Jie, F.
Horn, L.
ANNALS OF ONCOLOGY, 2019, 30 (07) : 1127 - 1133
[39] EFFICACY OF ERLOTINIB IN > 4,000 PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): ANALYSIS OF THE EUROPEAN SUBPOPULATION OF THE TRUST STUDY
Groen, H.
Barata, F.
McDermott, R.
Magyar, P.
Ardizzoni, A.
ANNALS OF ONCOLOGY, 2008, 19 : 101 - 101
[40] Erlotinib (Tarceva®) in patients with non-small-cell lung cancer (NSCLC): results on 394 patients from Tarceva Register of Czech Republic
Skrickova, Jana
Pesek, Milos
Zatloukal, Petr
Kolek, Vitezslav
Koubkova, Leona
Salajka, Frantisek
Zemanova, Milada
Tomiskova, Marcela
Sixtova, Dimka
Pavlik, Tomas
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S714 - S714

← 1 2 3 4 5 →